title: cdc25A is necessary but not sufficient for optimal c-myc-induced apoptosis and cell proliferation of vascular smooth muscle cells.
abstract: Increasing evidence indicates that the control of cell proliferation and apoptosis are linked. The c-myc proto-oncogene is induced early after cell-cycle entry in vascular smooth muscle cells (VSMCs) in vitro and after arterial injury and regulates both cell proliferation and apoptosis. Although both proliferation and apoptosis are likely to be mediated via transcriptional activation of target genes, few c-myc targets have been identified. Therefore, the recent identification that cdc25A, a cell-cycle phosphatase involved in G1 progression, is transcriptionally activated by c-myc and regulates c-myc-induced apoptosis has suggested that cdc25A may be the principal mediator of c-myc in VSMCs. We examined cdc25A regulation of c-myc-induced proliferation and apoptosis by expressing cdc25A or antisense cdc25A in primary rat VSMCs or in VSMCs expressing deregulated c-myc or adenovirus E1A. Ectopic c-myc increased cdc25A expression, but cdc25A was still responsive to serum components, which indicated that c-myc alone is not the main determinant of cdc25A expression. Antisense cdc25A inhibited c-myc-induced proliferation and apoptosis; however, drug and metabolic blocks indicated that this effect was limited to G1. Ectopic cdc25A augmented the proproliferative and proapoptotic action of c-myc but did not increase cell proliferation or apoptosis in the absence of ectopic c-myc. In contrast, E1A/E2F-induced apoptosis was independent of cdc25A. We conclude that cdc25A expression modulates the ability of c-myc to induce apoptosis in G1. However, cdc25A alone does not induce apoptosis and cannot substitute for c-myc in VSMCs. Additional targets of c-myc are therefore involved in apoptosis of both G1 and post-G1 VSMCs.
authors: Department of Medicine, Addenbrooke's Hospital, Cambridge, UK.
authors: K
authors: K
authors: Macdonald
authors: M R
authors: MR
authors: Bennett
mesh_terms: D000818:Animals; D001011:Aorta / Q000166:cytology; D017209:Apoptosis / Q000502:physiology*; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000502:physiology; D050684:E2F Transcription Factors; D005047:Etoposide / Q000494:pharmacology; D005434:Flow Cytometry; D016193:G1 Phase / Q000187:drug effects / Q000502:physiology; D007532:Isoleucine / Q000494:pharmacology; D008297:Male; D018715:Microscopy, Video; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000166:cytology* / Q000201:enzymology; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D017027:Protein Tyrosine Phosphatases / Q000096:biosynthesis*; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D056465:Retinoblastoma-Binding Protein 1; D016196:S Phase / Q000187:drug effects / Q000502:physiology; D050680:Transcription Factor DP1; D014157:Transcription Factors / Q000502:physiology; D020687:cdc25 Phosphatases
chemical_list: D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D019384:Nucleic Acid Synthesis Inhibitors; D016271:Proto-Oncogene Proteins c-myc; D056465:Retinoblastoma-Binding Protein 1; D050680:Transcription Factor DP1; D014157:Transcription Factors; D007532:Isoleucine; D005047:Etoposide; C517007:Cdc25a protein, rat; D017027:Protein Tyrosine Phosphatases; D020687:cdc25 Phosphatases